176 related articles for article (PubMed ID: 33374971)
1. Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib.
La Monica S; Fumarola C; Cretella D; Bonelli M; Minari R; Cavazzoni A; Digiacomo G; Galetti M; Volta F; Mancini M; Petronini PG; Tiseo M; Alfieri R
Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33374971
[TBL] [Abstract][Full Text] [Related]
2. CDK4/6 inhibitor palbociclib overcomes acquired resistance to third-generation EGFR inhibitor osimertinib in non-small cell lung cancer (NSCLC).
Qin Q; Li X; Liang X; Zeng L; Wang J; Sun L; Zhong D
Thorac Cancer; 2020 Sep; 11(9):2389-2397. PubMed ID: 32677256
[TBL] [Abstract][Full Text] [Related]
3. Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators.
Volta F; La Monica S; Leonetti A; Gnetti L; Bonelli M; Cavazzoni A; Fumarola C; Galetti M; Eltayeb K; Minari R; Petronini PG; Tiseo M; Alfieri R
Target Oncol; 2023 Nov; 18(6):953-964. PubMed ID: 37855989
[TBL] [Abstract][Full Text] [Related]
4. Abemaciclib, a Selective CDK4/6 Inhibitor, Enhances the Radiosensitivity of Non-Small Cell Lung Cancer
Naz S; Sowers A; Choudhuri R; Wissler M; Gamson J; Mathias A; Cook JA; Mitchell JB
Clin Cancer Res; 2018 Aug; 24(16):3994-4005. PubMed ID: 29716919
[No Abstract] [Full Text] [Related]
5. Impact of apatinib in combination with osimertinib on EGFR T790M-positive lung adenocarcinoma.
Liu Y; Xiong ZC; Sun X; Sun L; Zhang SL; Ma JT; Han CB
Transl Cancer Res; 2019 Sep; 8(5):2151-2163. PubMed ID: 35116965
[TBL] [Abstract][Full Text] [Related]
6. CDK4/6 signaling attenuates the effect of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in
Hara N; Ichihara E; Kano H; Ando C; Morita A; Nishi T; Okawa S; Nakasuka T; Hirabae A; Abe M; Asada N; Ninomiya K; Makimoto G; Fujii M; Kubo T; Ohashi K; Hotta K; Tabata M; Maeda Y; Kiura K
Transl Lung Cancer Res; 2023 Oct; 12(10):2098-2112. PubMed ID: 38025818
[TBL] [Abstract][Full Text] [Related]
7. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.
Tong X; Tanino R; Sun R; Tsubata Y; Okimoto T; Takechi M; Isobe T
Respir Res; 2019 Dec; 20(1):270. PubMed ID: 31791326
[TBL] [Abstract][Full Text] [Related]
8. Trichostatin A downregulates bromodomain and extra-terminal proteins to suppress osimertinib resistant non-small cell lung carcinoma.
Meng Y; Qian X; Zhao L; Li N; Wu S; Chen B; Sun T; Wang X
Cancer Cell Int; 2021 Apr; 21(1):216. PubMed ID: 33858423
[TBL] [Abstract][Full Text] [Related]
9. Luteolin overcomes acquired resistance to osimertinib in non-small cell lung cancer cells by targeting the HGF-MET-Akt pathway.
Huang G; Liu X; Jiang T; Cao Y; Sang M; Song X; Zhou B; Qu H; Cai H; Xing D; Mao Y; Lin G; Liu X; Zheng X
Am J Cancer Res; 2023; 13(9):4145-4162. PubMed ID: 37818074
[TBL] [Abstract][Full Text] [Related]
10. Hsp90 inhibitors enhance the antitumoral effect of osimertinib in parental and osimertinib-resistant non-small cell lung cancer cell lines.
Codony-Servat J; Viteri S; Codony-Servat C; Ito M; Bracht JWP; Berenguer J; Chaib I; Molina-Vila MA; Karachaliou N; Rosell R
Transl Lung Cancer Res; 2019 Aug; 8(4):340-351. PubMed ID: 31555510
[TBL] [Abstract][Full Text] [Related]
11. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
[TBL] [Abstract][Full Text] [Related]
12. PIM1 inhibitor synergizes the anti-tumor effect of osimertinib via STAT3 dephosphorylation in EGFR-mutant non-small cell lung cancer.
Sun Z; Zeng L; Zhang M; Zhang Y; Yang N
Ann Transl Med; 2020 Mar; 8(6):366. PubMed ID: 32355810
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR.
Della Corte CM; Malapelle U; Vigliar E; Pepe F; Troncone G; Ciaramella V; Troiani T; Martinelli E; Belli V; Ciardiello F; Morgillo F
Oncotarget; 2017 Apr; 8(14):23020-23032. PubMed ID: 28416737
[TBL] [Abstract][Full Text] [Related]
14. TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells.
Wu DW; Chen TC; Huang HS; Lee H
Cell Death Dis; 2016 Jun; 7(6):e2290. PubMed ID: 27362807
[TBL] [Abstract][Full Text] [Related]
15. Estrogen receptor β1 activation accelerates resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in non-small cell lung cancer.
Fu S; Liu C; Huang Q; Fan S; Tang H; Fu X; Ai B; Liao Y; Chu Q
Oncol Rep; 2018 Mar; 39(3):1313-1321. PubMed ID: 29328407
[TBL] [Abstract][Full Text] [Related]
16. A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group.
Jiang T; Su C; Ren S; Cappuzzo F; Rocco G; Palmer JD; van Zandwijk N; Blackhall F; Le X; Pennell NA; Zhou C;
J Thorac Dis; 2018 Jul; 10(7):3909-3921. PubMed ID: 30174832
[TBL] [Abstract][Full Text] [Related]
17. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.
Jang JY; Kim YG; Nam SJ; Keam B; Kim TM; Jeon YK; Kim CW
Mol Cancer Ther; 2016 Jun; 15(6):1387-96. PubMed ID: 26883272
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacological Effects of CDK4 & 6 Selective Inhibitor Abemaciclib in Hormone Receptor-Positive Breast Cancer].
Tamaki C; Hayashi S; Sato A; Maeda K; Sakaguchi S; Buchanan S; Enatsu S
Gan To Kagaku Ryoho; 2019 Sep; 46(9):1405-1411. PubMed ID: 31530780
[TBL] [Abstract][Full Text] [Related]
19. Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation.
La Monica S; Madeddu D; Tiseo M; Vivo V; Galetti M; Cretella D; Bonelli M; Fumarola C; Cavazzoni A; Falco A; Gervasi A; Lagrasta CA; Naldi N; Barocelli E; Ardizzoni A; Quaini F; Petronini PG; Alfieri R
J Thorac Oncol; 2016 Jul; 11(7):1051-63. PubMed ID: 27006151
[TBL] [Abstract][Full Text] [Related]
20. Predictive efficacy of (11)C-PD153035 PET imaging for EGFR-tyrosine kinase inhibitor sensitivity in non-small cell lung cancer patients.
Dai D; Li XF; Wang J; Liu JJ; Zhu YJ; Zhang Y; Wang Q; Xu WG
Int J Cancer; 2016 Feb; 138(4):1003-12. PubMed ID: 26334931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
